首页 | 本学科首页   官方微博 | 高级检索  
检索        

  Deferoxamine is an iron-chelating agent, used in the treatmentof acute iron intoxication and chronic iron overload secondaryto multiple blood transfusions. Moreover it is currently recommendedby the K/DOQI clinical practice guidelines for bone metabolismand disease in chronic kidney disease (CKD) for treatment insymptomatic aluminium toxicity 1]. Deferoxamine is known tohave many adverse effects, some of them potentially fatal, especiallyinfections with siderophilic organisms like mucormycosis 2].We report a case of acute tubular injury in a renal transplantrecipient secondary to treatment with deferoxamine due to ironoverload, in the context of autoimmune haemolytic anaemia.   A 58-year-old Caucasian male, with 21-year status post-cadaverkidney transplantation due to Goodpasture's syndrome, presentedwith a sudden rise in serum creatinine from 120 µmol/Lto 250 µmol/L (Figure 1

Acute kidney injury due to deferoxamine in a renal transplant patient.
Authors:Christian Clajus  Jan U Becker  Dirk O Stichtenoth  Jessica Wortmann  Anke Schwarz  Jan T Kielstein
Institution:Department of Nephrology, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
Abstract:   Introduction    Case report
Keywords:chronic kidney disease  deferoxamine  renal biopsy  toxicity
本文献已被 Oxford 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号